The influence of treatment with estrogens and estramustine phosphate on platelet aggregation and plasma lipoproteins in non-disseminated prostatic carcinoma

摘要: The treatment of prostatic carcinoma with estrogens is associated an increased risk cardiovascular as well thromboembolic complications. In the present study, patients harboring highly or moderately differentiated without signs metastases were treated either polyestradiolphosphate + etinylestradiol, estramustine phosphate given no treatment. Subsequently, these investigated regarding factors (platelet aggregation, plasma and platelet phospholipid composition lipoprotein patterns) that might contribute to thrombogenesis risk. results indicate presence in vitro aggregation etinylestradiol compared those A possible relationship between availability arachidonic acid membrane phospholipids suggested. On other hand alterations lipoproteins observed during are generally considered positive from atherogenic point view do not seem relevant elevated incidence disease patients.